HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Moving Toward Personalized Care: Liquid Biopsy Predicts Response to Cisplatin in an Unusual Case of BRCA2-Null Neuroendocrine Prostate Cancer.

AuthorsEdmund C P Chedgy, Matti Annala, Kevin Beja, Evan W Warner, Martin E Gleave, Kim N Chi, Alexander W Wyatt
JournalClinical genitourinary cancer (Clin Genitourin Cancer) Vol. 14 Issue 2 Pg. e233-6 (Apr 2016) ISSN: 1938-0682 [Electronic] United States
PMID26797585 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antineoplastic Agents
  • BRCA2 Protein
  • BRCA2 protein, human
  • Cisplatin
Topics
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • BRCA2 Protein (genetics)
  • Carcinoma, Neuroendocrine (drug therapy, genetics)
  • Cisplatin (administration & dosage, therapeutic use)
  • Gene Deletion
  • Humans
  • Male
  • Middle Aged
  • Precision Medicine
  • Prostatic Neoplasms (drug therapy, genetics)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: